Why the study?
Does intravenous verapamil alter acute hemodynamic function in patients with coronary artery disease?
Does intravenous verapamil alter acute hemodynamic function in patients with coronary artery disease?
Intravenous verapamil exerts a transient, dose- and time-dependent depressant effect on left ventricular function in patients with coronary artery disease, but is generally safe due to quick recovery.
Answers are grounded in this paper and cite their sources.
Differential EF response suggests caution with IV verapamil in low-EF CAD; leaves open need for randomized safety data.
The acute hemodynamic effects of an i.v. bolus of verapamil, 0.1 mg/kg or 0.06-0.075 mg/kg, were examined by serial radionuclide studies in 46 patients with coronary artery disease. In 20 patients with ejection fractions (EFs) greater than 35% (group 1A), verapamil, 0.1 mg/kg given over 1-11/2 minutes, had a biphasic effect: first, a transient decrease in EF accompanied by increased left ventricular (LV) volumes and cardiac output equivalents; then, an overshoot of EF to values above control, accompanied by a decrease in peripheral vascular resistance and a drastic decrease in LV volumes, while cardiac output equivalent remained slightly elevated. In eight patients with EFs less than 35% (group 1B), only the first effect on EF was noted. In 10 patients with EFs greater than 35% (group 2), verapamil, 0.06-0.075 mg/kg, exerted qualitatively similar but milder effects on hemodynamic function. Finally, verapamil, 0.1 mg/kg given more slowly, over 2-21/2 minutes, produced no significant changes in EF or LV volumes in another eight patients (group 3). The acute effects of verapamil are thus both time-related and dose-dependent. They are also related to the baseline functional reserve of the left ventricle. This study documents that verapamil exerts a depressant effect on LV function. However, the transient nature of this depression and the quick recovery to normal or above-normal values indicate that verapamil, in the doses used in this study, is safe to use intravenously in patients with coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Klein et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: